GLP-1 Side Effects: Complete Guide for 2026: Semaglutide, Tirzepatide, Wegovy

Complete Side Effect Overview with Incidence Rates

GLP-1 receptor agonists are among the most effective medications for weight loss and diabetes management ever developed. Like all medications, they come with potential side effects. Understanding what to expect, how often side effects occur, and how to manage them helps you to navigate your treatment with confidence.

The side effects of GLP-1 medications are well-characterized through extensive clinical trial programs involving tens of thousands of participants. The STEP trials for semaglutide, the SURMOUNT trials for tirzepatide, and the SCALE trials for liraglutide provide strong data on what patients can expect. Post-marketing surveillance from millions of real-world users provides additional data on rare side effects that may not appear in clinical trials.

How Side Effects Are Classified

Side effects are classified by frequency and severity. Frequency categories used in clinical trials include:

• Very common: Affects more than 1 in 10 patients (>10%)
• Common: Affects 1-10 in 100 patients (1-10%)
• Uncommon: Affects 1-10 in 1,000 patients (0.1-1%)
• Rare: Affects 1-10 in 10,000 patients (0.01-0.1%)
• Very rare: Affects fewer than 1 in 10,000 patients (<0.01%)

Severity is classified as mild (does not interfere with daily activities), moderate (somewhat interferes with daily activities), or severe (significantly interferes with daily activities or requires medical intervention). The majority of GLP-1 side effects fall into the mild to moderate categories.

Why Do GLP-1 Medications Cause These Side Effects?

Understanding why GLP-1 medications cause their side effects helps contextualize them and reduces anxiety. GLP-1 (glucagon-like peptide-1) is a natural hormone produced by your intestines after eating. GLP-1 receptor agonist medications mimic this hormone but at much higher and more sustained levels than the body naturally produces.

GLP-1 receptors are found throughout the body, not just in the pancreas and gut. They exist in the brain, heart, kidneys, immune system, and gastrointestinal tract. When these receptors are activated by the medication, they produce effects in all of these organs, which explains the wide range of both benefits and side effects.

In the gastrointestinal tract, GLP-1 receptor activation slows gastric emptying (how quickly food leaves your stomach), reduces intestinal motility, and suppresses gastric acid secretion. These effects contribute to the appetite-suppressing benefits of the medication but also cause nausea, vomiting, constipation, and other GI symptoms. The body gradually adapts to these effects, which is why GI side effects typically improve over time.

In the brain, GLP-1 receptor activation in the hypothalamus reduces appetite and food cravings. It may also affect mood, sleep, and reward pathways. In the heart and blood vessels, GLP-1 receptor activation produces beneficial effects on blood pressure, inflammation, and cardiovascular risk. Understanding that the medication works through multiple pathways explains why its effects extend beyond simple appetite reduction.

Discontinuation Rates Due to Side Effects

An important metric for understanding the real-world impact of side effects is the percentage of patients who stop their medication because of them. In clinical trials, these rates were relatively low:

• Semaglutide 2.4 mg: 7% discontinued due to adverse events (vs 3% on placebo)
• Tirzepatide 15 mg: 7% discontinued due to adverse events (vs 2% on placebo)
• Tirzepatide 5 mg: 4% discontinued due to adverse events
• Liraglutide 3.0 mg: 10% discontinued due to adverse events (vs 4% on placebo)

These numbers mean that 90-96% of patients were able to continue treatment despite experiencing side effects. The gradual dose-escalation protocols, combined with management strategies, make side effects tolerable for the vast majority of patients. real-world discontinuation rates tend to be higher than clinical trial rates due to less structured support and follow-up.

GI Side Effects Deep-Dive: Nausea, Vomiting, Diarrhea, Constipation, and GERD

Gastrointestinal side effects are by far the most common side effects of GLP-1 medications. They are the primary reason patients seek management advice and the leading cause of medication discontinuation. Understanding the mechanisms, timeline, and management of each GI symptom is essential for a successful treatment experience.

Nausea

Nausea is the single most reported side effect of GLP-1 medications, affecting 31-44% of patients depending on the specific medication and dose. It results from the combination of delayed gastric emptying (food sitting in the stomach longer), direct activation of nausea centers in the brainstem, and changes in gut motility.

The nausea associated with GLP-1 medications has a characteristic pattern. It tends to be worst during the first 1-2 weeks after starting the medication or increasing the dose. Most patients describe it as a persistent, low-grade queasiness rather than the acute nausea associated with food poisoning or stomach flu. It is often worse on an empty stomach and after eating large or fatty meals.

For most patients, nausea follows a predictable improvement curve. During weeks 1-2 of a new dose, nausea may be present for several hours each day. By weeks 3-4, it typically reduces to brief episodes. By weeks 6-8, most patients experience minimal or no nausea at their current dose. However, each dose escalation may temporarily reintroduce nausea, typically less severely than the initial experience.

A minority of patients (estimated at 5-10%) experience persistent nausea that does not fully resolve with time. These patients may benefit from a slower dose escalation, a lower maintenance dose, or the addition of anti-nausea medication. For a detailed guide on managing nausea, see our Semaglutide Nausea Management Guide.

Vomiting

Vomiting occurs in approximately 13-24% of GLP-1 patients, making it less common than nausea but more disruptive when it occurs. Like nausea, vomiting is most common during the first weeks of treatment or dose escalation and typically improves with time.

Most patients who experience vomiting have isolated episodes rather than recurrent daily vomiting. Common triggers include eating too much at one sitting (the reduced stomach capacity catches patients off guard), eating very fatty or greasy foods, eating too quickly, and lying down after meals.

Vomiting that is persistent (multiple episodes per day for several consecutive days) warrants medical attention because it can lead to dehydration, electrolyte imbalances, and medication malabsorption. If you are taking other medications and vomiting within 1-2 hours of taking them, those medications may not be fully absorbed.

Strategies to reduce vomiting include eating very small meals (half your normal portion), chewing food thoroughly and eating slowly, avoiding foods known to trigger nausea for you personally, staying upright for at least 30 minutes after eating, and discussing anti-emetic medication with your provider if episodes are frequent.

One often-overlooked concern with recurrent vomiting is the impact on dental health. Stomach acid that comes into contact with tooth enamel during vomiting episodes can cause erosion over time. If you experience frequent vomiting, rinse your mouth with water or a baking soda solution (one teaspoon of baking soda in a glass of water) rather than brushing immediately, as brushing can spread the acid across enamel surfaces. Mention recurrent vomiting to your dentist so they can monitor for early signs of enamel damage.

Timing your injection may also help reduce vomiting. Some patients find that injecting in the evening rather than the morning allows the initial wave of nausea to pass during sleep. Others find that injecting on a day when they can rest and eat lightly is helpful. Your healthcare provider can work with you to find the best injection schedule that minimizes disruption to your daily life. Keeping a simple log of when vomiting occurs in relation to meals, injection timing, and specific foods can help identify personal patterns and triggers.

Diarrhea

Diarrhea affects approximately 21-30% of GLP-1 patients. It can occur at any point during treatment but is most common during dose escalation. The mechanism involves changes in intestinal motility, shifts in the gut microbiome, and altered bile acid metabolism.

GLP-1-related diarrhea typically presents as loose, watery stools occurring 2-4 times per day during acute episodes. It may alternate with periods of normal bowel function. Some patients experience diarrhea and constipation at different times during their treatment, which can be confusing but is a recognized pattern.

Important considerations for managing diarrhea on GLP-1 therapy include hydration (diarrhea increases fluid losses significantly), electrolyte replacement (particularly sodium and potassium), and monitoring for signs of dehydration (dark urine, thirst, dizziness, dry mouth). If diarrhea contains blood, is accompanied by high fever, or persists for more than 5-7 days, contact your healthcare provider.

Dietary modifications that can help include reducing intake of fatty and fried foods, limiting artificial sweeteners (especially sugar alcohols like sorbitol and maltitol), temporarily reducing high-fiber foods if they seem to worsen symptoms, and eating smaller meals. Probiotics may also help some patients restore normal gut function.

Constipation

Constipation affects approximately 12-24% of GLP-1 patients and is a direct consequence of the medication's effect on slowing gut motility. As food moves more slowly through the digestive tract, more water is absorbed from the stool, making it harder and more difficult to pass.

Several factors compound constipation during GLP-1 therapy. Reduced food intake means less bulk in the digestive system to stimulate peristalsis (the wave-like contractions that move food through the intestines). Reduced fluid intake (common when appetite is suppressed) further dehydrates stool. And reduced physical activity (which some patients experience during early treatment) removes another stimulus for healthy bowel function.

Management strategies for GLP-1-related constipation include drinking at least 64 ounces of water daily, consuming adequate fiber (25-30 grams per day) from fruits, vegetables, and whole grains, staying physically active (even a daily 20-minute walk helps), and using over-the-counter remedies when needed. Osmotic laxatives like polyethylene glycol (Miralax) are generally safe for regular use. Fiber supplements like psyllium husk (Metamucil) add bulk to stool. Stool softeners like docusate (Colace) can prevent straining.

Avoid stimulant laxatives (like bisacodyl or senna) as a first-line treatment, as regular use can lead to dependence. If constipation is severe (no bowel movement for 5+ days) or accompanied by significant pain or abdominal distension, contact your healthcare provider.

Gastroesophageal Reflux Disease (GERD) and Acid Reflux

GERD and acid reflux symptoms are reported by approximately 4-5% of GLP-1 patients in clinical trials, though anecdotal reports suggest the real-world prevalence may be higher. The delayed gastric emptying caused by GLP-1 medications means food and stomach acid sit in the stomach longer, increasing the opportunity for reflux into the esophagus.

Symptoms of GERD include heartburn (burning sensation behind the breastbone), acid taste in the mouth, regurgitation of food or acid, chest discomfort, difficulty swallowing, and a chronic cough. Patients who had pre-existing GERD before starting GLP-1 therapy may find their symptoms worsen.

Management of GERD during GLP-1 therapy includes eating smaller meals, avoiding eating within 3 hours of bedtime, elevating the head of the bed 6-8 inches, avoiding trigger foods (citrus, tomatoes, chocolate, caffeine, alcohol, spicy foods, mint), wearing loose-fitting clothing, and maintaining a healthy weight (which GLP-1 therapy itself helps achieve). Over-the-counter antacids, H2 blockers (famotidine), or proton pump inhibitors (omeprazole) can provide additional relief. Discuss persistent GERD symptoms with your provider.

Abdominal Pain and Bloating

Abdominal pain affects approximately 14-20% of GLP-1 patients, and bloating (abdominal distension) affects approximately 5-7%. These symptoms often accompany other GI side effects like nausea, constipation, or diarrhea.

The abdominal pain associated with GLP-1 medications is typically described as cramping, fullness, or pressure in the upper or mid-abdomen. It is usually mild to moderate and often related to meal timing. Pain that is severe, persistent, localized to one area, or accompanied by fever is a red flag that requires medical evaluation to rule out pancreatitis or gallbladder disease.

Bloating results from the slower movement of food and gas through the digestive system. It can be exacerbated by high-fiber foods, carbonated beverages, sugar-free products containing sugar alcohols, and swallowing air while eating or drinking. Eating slowly, avoiding carbonated drinks, limiting sugar-free gum and candies, and gentle physical activity after meals can all help reduce bloating.

Injection Site Reactions

Because most GLP-1 medications for weight loss are administered as subcutaneous injections (either weekly or daily), injection site reactions are a common concern. These reactions are typically mild and manageable but can be bothersome for patients who are new to self-injection.

Types of Injection Site Reactions

Redness (erythema): The most common injection site reaction, affecting 2-4% of patients. A small area of redness appears around the injection site within hours and typically resolves within 1-3 days. This is usually a normal inflammatory response to the injection itself rather than an allergic reaction to the medication.

Itching (pruritus): Mild itching at the injection site occurs in 1-3% of patients. It usually begins within hours of injection and resolves within 24-48 hours. Antihistamines can provide relief if itching is bothersome.

Pain or tenderness: Mild pain at the injection site is reported by 1-3% of patients. It is typically brief (lasting minutes to hours) and is influenced by injection technique, needle size, and injection site.

Swelling or induration: Small areas of swelling or firmness at the injection site occur in less than 2% of patients. These usually resolve within a few days. Persistent hard lumps (lipohypertrophy) are rare but can develop with repeated injections at the same site.

Bruising: Minor bruising at the injection site is common, particularly if a blood vessel is nicked during injection. It is not specific to GLP-1 medications and occurs with any subcutaneous injection.

Reducing Injection Site Reactions

Several strategies can minimize injection site discomfort and reactions:

• Rotate injection sites. Use a different site for each injection, rotating between the abdomen, thigh, and upper arm. Within each general area, vary the exact location by at least 1 inch from the previous injection. This prevents tissue irritation from repeated injections at the same spot.
• Allow the medication to reach room temperature. If stored in the refrigerator, let the pen or vial sit at room temperature for 15-30 minutes before injecting. Cold medication can sting more upon injection.
• Use proper technique. Inject at a 90-degree angle into a pinched fold of skin. Insert the needle smoothly and inject slowly. Hold the needle in place for 5-10 seconds after completing the injection before withdrawing. See our GLP-1 Injection Guide for detailed instructions.
• Do not rub the injection site. Rubbing can increase local irritation and bruising. Gentle pressure with a cotton ball is acceptable.
• Apply ice before injection. If pain is a concern, applying an ice cube to the injection site for 30-60 seconds before injecting can numb the area and reduce discomfort.

When to Contact Your Provider About Injection Site Reactions

Most injection site reactions are harmless and self-limiting. However, contact your healthcare provider if you experience spreading redness that extends more than 2 inches from the injection site, signs of infection (increasing pain, warmth, pus, red streaking), a large or growing hard lump at the injection site, a rash or hives that extends beyond the injection site (possible allergic reaction), or persistent reactions that occur with every injection despite site rotation.

Serious Side Effects: Pancreatitis, Gallbladder, Thyroid, and Kidney

While the vast majority of GLP-1 side effects are mild and temporary, there are several serious side effects that, while rare, require awareness and prompt action if they occur. Understanding these risks allows you to monitor for warning signs and seek appropriate care quickly.

Pancreatitis

Acute pancreatitis (inflammation of the pancreas) is the most discussed serious side effect of GLP-1 medications. It occurs in approximately 0.2-0.4% of patients in clinical trials, compared to 0.1-0.2% on placebo. While this represents a small absolute increase in risk, pancreatitis is a serious condition that can become life-threatening if not treated promptly.

How GLP-1 medications may increase pancreatitis risk: GLP-1 receptors are present on pancreatic cells, and activation of these receptors increases pancreatic secretions. The exact mechanism by which this may lead to pancreatitis is not fully understood, but it may involve overstimulation of pancreatic acinar cells, increased pressure in the pancreatic duct, or an inflammatory response. Patients with a history of pancreatitis, heavy alcohol use, very high triglycerides, or gallstones are at higher baseline risk.

Symptoms of pancreatitis: The hallmark symptom is severe, persistent upper abdominal pain that often radiates to the back. The pain is typically worse after eating and may be partially relieved by leaning forward. Other symptoms include nausea and vomiting, fever, rapid heartbeat, and abdominal tenderness. The pain of pancreatitis is usually significantly more severe than typical GI discomfort from GLP-1 medications.

What to do: If you experience severe, persistent abdominal pain, especially if it radiates to the back, seek emergency medical care immediately. Pancreatitis is diagnosed through blood tests (elevated lipase and amylase) and imaging (CT scan or ultrasound). If pancreatitis is confirmed, the GLP-1 medication is typically discontinued permanently, as restarting it could trigger another episode.

Gallbladder Disease

Gallbladder events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), occur in approximately 1.5-2.5% of GLP-1 patients, compared to 0.5-1% on placebo. This increased risk is not unique to GLP-1 medications; rapid weight loss from any cause (dieting, surgery, illness) increases gallstone risk.

Why weight loss increases gallstone risk: During weight loss, the liver secretes more cholesterol into bile, while the gallbladder contracts less frequently (because you are eating less fat, which triggers gallbladder contractions). The combination of cholesterol-supersaturated bile and reduced gallbladder emptying creates ideal conditions for cholesterol crystals to form and grow into gallstones.

Symptoms of gallstone problems: The classic presentation is intermittent right upper abdominal pain (biliary colic), especially after eating fatty meals. The pain may radiate to the right shoulder or back. Episodes typically last 30 minutes to several hours. Acute cholecystitis (gallbladder inflammation, usually from a gallstone blocking the gallbladder duct) presents with persistent right upper abdominal pain, fever, nausea, and vomiting.

Risk reduction: While gallstones cannot be completely prevented during weight loss, several strategies may reduce risk. Avoiding very rapid weight loss (more than 3 pounds per week) reduces the metabolic stress that promotes stone formation. Including small amounts of healthy fat in your diet stimulates gallbladder contractions and prevents bile stasis. Adequate fiber intake binds bile salts and may reduce cholesterol saturation of bile. Some physicians prescribe ursodiol (ursodeoxycholic acid) prophylactically for patients at high risk.

For a comprehensive discussion of gallbladder health during semaglutide therapy, see our Semaglutide and Gallbladder Guide.

Thyroid Concerns (Medullary Thyroid Carcinoma Warning)

All GLP-1 receptor agonists carry a boxed warning (the FDA's most serious warning) regarding the risk of medullary thyroid carcinoma (MTC). This warning is based on animal studies in which rodents developed thyroid C-cell tumors when exposed to GLP-1 receptor agonists at doses many times higher than human therapeutic doses.

The animal data: In rats and mice, long-term exposure to liraglutide, semaglutide, and tirzepatide caused dose-dependent increases in thyroid C-cell tumors, including MTC. This effect was consistent across multiple GLP-1 medications and appeared to be a class effect related to GLP-1 receptor activation on thyroid C-cells.

The human data: the animal findings have not been replicated in humans. Rodent thyroid C-cells express much higher levels of GLP-1 receptors than human C-cells, which may explain why they are more susceptible to this effect. Large epidemiological studies and post-marketing surveillance involving millions of patients have not demonstrated an increased risk of MTC or other thyroid cancers in humans taking GLP-1 medications. The LEADER and SUSTAIN trials for liraglutide and semaglutide, which followed patients for 3-5 years, showed no increase in thyroid cancer.

Contraindications: Despite the lack of confirmed human risk, GLP-1 medications are contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). These patients have inherently higher risk for thyroid C-cell tumors and should not be exposed to any potential additional risk.

Monitoring: There are no routine thyroid screening recommendations specifically for GLP-1 patients. However, if you develop a lump or swelling in your neck, difficulty swallowing, persistent hoarseness, or shortness of breath, these symptoms should be evaluated promptly regardless of GLP-1 use.

Kidney Effects

Acute kidney injury (AKI) has been reported in post-marketing surveillance of GLP-1 medications, though it was rare in clinical trials. The primary mechanism is dehydration resulting from severe GI side effects (vomiting and diarrhea) rather than a direct toxic effect on the kidneys.

When the body becomes dehydrated, blood flow to the kidneys decreases, reducing their ability to filter waste products. Severe or prolonged dehydration can cause acute kidney damage. Patients with pre-existing kidney disease, those taking other medications that affect the kidneys (NSAIDs, certain blood pressure medications), and older adults are at higher risk.

Prevention: The best prevention is staying adequately hydrated, especially during periods of GI side effects. If you experience persistent vomiting or diarrhea, increase your fluid intake. If you cannot keep fluids down for 24 hours, seek medical attention for IV hydration. Have your kidney function (creatinine and GFR) monitored at baseline and periodically during treatment, especially if you have risk factors.

Symptoms of kidney problems: Signs that may indicate kidney stress include significantly reduced urine output, very dark or tea-colored urine, swelling in the legs or ankles, persistent nausea with back or flank pain, and generalized fatigue. If you experience these symptoms, especially during a period of GI illness, contact your provider promptly.

For more information about kidney health during GLP-1 therapy, see our Semaglutide and Kidney Health Guide.

Mental Health Effects

The relationship between GLP-1 medications and mental health has received increasing attention from researchers, clinicians, and patients. While clinical trials did not show significantly higher rates of depression or suicidal ideation in GLP-1 groups compared to placebo, post-marketing reports and patient experiences have raised important questions that deserve thorough discussion.

Depression and Mood Changes

Some patients report changes in mood while taking GLP-1 medications, including feelings of sadness, irritability, apathy, or decreased motivation. In the STEP trials, the incidence of depression-related adverse events was approximately 1.5% in the semaglutide group compared to 1% in the placebo group. While this difference was not statistically significant, it prompted ongoing monitoring.

Several factors can contribute to mood changes during GLP-1 therapy that may not be directly caused by the medication:

Calorie restriction itself. Eating significantly fewer calories can affect neurotransmitter production, particularly serotonin (the "feel-good" neurotransmitter). Serotonin is primarily produced in the gut and requires adequate tryptophan (an amino acid from protein) for production. When protein intake drops, serotonin production may decrease, contributing to low mood.

Changed relationship with food. For many people, food provides comfort, pleasure, and social connection. When GLP-1 medications dramatically reduce appetite and food enjoyment, patients can experience a genuine sense of loss. The pleasure they previously derived from meals, cooking, dining out, and food-centered social activities may be significantly diminished. This can feel like a form of grief that manifests as sadness or apathy.

Reduced reward system activity. Emerging research suggests that GLP-1 receptor agonists may reduce activity in the brain's reward circuits, which extend beyond food to include other sources of pleasure. Some patients report reduced enjoyment of activities they previously found pleasurable, reduced motivation, and a general "flatness" of emotion. This is an active area of research that is not yet fully understood.

Body image adjustment. Rapid physical changes can be psychologically disorienting. Some patients feel uncomfortable in their changing body, experience identity confusion (particularly if their weight was a significant part of their identity), or find that weight loss does not provide the emotional relief they expected. This disconnect between expectations and reality can contribute to disappointment and low mood.

Social changes. Weight loss can change social dynamics in unexpected ways. Relationships may shift, unwanted attention from others can cause discomfort, and the constant commentary about your appearance from friends and family, even when well-intentioned, can become exhausting.

Anxiety

Anxiety during GLP-1 therapy can stem from multiple sources. Health anxiety about potential side effects, concern about the safety of a relatively new medication class, worry about what happens when the medication is stopped, and the stress of major lifestyle and body changes can all contribute. Additionally, the physiological effects of reduced calorie intake (including blood sugar fluctuations and hormonal changes) can produce physical symptoms that mimic anxiety, such as heart palpitations, restlessness, and difficulty concentrating.

Suicidal Ideation

In mid-2023, the European Medicines Agency (EMA) and later the FDA began reviewing reports of suicidal ideation in patients taking GLP-1 medications. As of early 2026, the FDA's review has not found sufficient evidence to establish a causal link between GLP-1 medications and suicidal thoughts or actions. However, monitoring continues, and the prescribing information now includes language about reporting mental health changes to healthcare providers.

If you experience new or worsening thoughts of self-harm or suicide while taking any medication, seek immediate help. Contact the 988 Suicide and Crisis Lifeline (call or text 988), go to your nearest emergency room, or contact your healthcare provider. These symptoms are always a medical emergency regardless of their cause.

Positive Mental Health Effects

many patients experience significant positive mental health effects from GLP-1 therapy. Weight loss can improve self-esteem, body image, and confidence. Reduced cravings and the feeling of control over eating can relieve the psychological burden of constant food preoccupation. Improved physical health, mobility, and energy can enhance mood and quality of life. Many patients report feeling more engaged in social activities, more confident in their appearance, and more optimistic about their future health.

The overall mental health impact of GLP-1 therapy is likely net-positive for most patients, but those who experience negative mood changes deserve support and appropriate treatment adjustments.

Food-Related Grief and Identity Changes

A psychological side effect that many patients do not anticipate is what some clinicians call food-related grief. For many people, food plays a central role in social gatherings, cultural traditions, family bonding, and emotional comfort. When GLP-1 medications dramatically reduce appetite and change the relationship with food, some patients experience a genuine sense of loss.

This can manifest as feeling disconnected during family meals, losing interest in cooking or dining out that was previously enjoyable, grieving the comfort that food once provided during stressful times, or feeling uncertain about how to participate in social events centered around eating. These feelings are normal and do not mean the medication is wrong for you. Many patients find it helpful to develop new rituals around meals that focus on connection and conversation rather than the food itself.

Some patients also report identity shifts as their body changes rapidly. Adjusting to a different physical appearance, receiving new attention or comments from others, and re-evaluating long-held beliefs about body image can all create emotional complexity. Working with a therapist who understands weight management and body image concerns can be especially valuable during this transition period.

Recommendations for Mental Health Monitoring

• Assess your baseline mental health before starting GLP-1 therapy. If you have a history of depression, anxiety, or eating disorders, discuss this with your provider.
• Monitor your mood regularly during treatment. Keeping a brief daily mood log can help identify patterns and changes.
• Report any significant mood changes to your provider promptly.
• Maintain social connections, physical activity, and other non-food sources of pleasure and meaning during your weight loss process.
• Consider therapy or counseling, particularly if you have a history of emotional eating, body image issues, or eating disorders.
• Ensure adequate protein and nutrient intake, which supports neurotransmitter production.
• Prioritize sleep, which is critical for emotional regulation.

Hair Loss and Skin Changes

Hair Loss (Telogen Effluvium)

Hair loss is reported by approximately 3-5% of patients on GLP-1 medications, with some surveys suggesting even higher rates among real-world users. The medical term for this type of hair loss is telogen effluvium, which refers to excessive shedding of hair that has entered the resting (telogen) phase of the growth cycle prematurely.

Telogen effluvium is not specific to GLP-1 medications. It occurs during any period of significant physiological stress, including rapid weight loss from any cause, major surgery, severe illness, hormonal changes, and nutritional deficiencies. The hair loss typically begins 2-4 months after the triggering event and can last for 3-6 months before resolving on its own as the body adjusts.

Mechanism: When the body undergoes significant stress or nutrient restriction, it redirects resources away from non-essential functions like hair growth. A larger-than-normal percentage of hair follicles enter the telogen (resting) phase simultaneously. After 2-4 months in the resting phase, these hairs fall out as new hairs begin growing in the same follicles. The result is a period of noticeable shedding that can be alarming but is usually temporary.

Risk factors for hair loss on GLP-1 therapy:

• Rapid weight loss (more than 2-3 pounds per week)
• Inadequate protein intake (protein provides the building blocks for hair)
• Iron deficiency (common in women and worsened by reduced food intake)
• Zinc deficiency (zinc is essential for hair follicle function)
• Biotin deficiency (though this is rare with a varied diet)
• Thyroid dysfunction (should be checked if hair loss is significant)
• Pre-existing hair thinning or genetic predisposition

Management and prevention:

• Ensure adequate protein intake (1.0-1.2g per pound of ideal body weight). See our Muscle Loss Prevention Guide for protein strategies.
• Have iron levels (ferritin) checked and supplement if below 50 ng/mL.
• Consider a zinc supplement (15-30mg daily) if dietary intake is low.
• Aim for gradual weight loss rather than rapid loss.
• Biotin supplementation (2,500-5,000 mcg daily) is commonly recommended, though evidence for its effectiveness in telogen effluvium is limited.
• Avoid harsh hair treatments, tight hairstyles, and excessive heat styling during the shedding period.
• Be patient. Telogen effluvium almost always resolves once the triggering stress has stabilized, with new hair growth visible within 3-6 months.

Skin Changes

Several skin changes can occur during GLP-1 therapy, mostly related to weight loss rather than direct medication effects:

Loose or sagging skin. Rapid loss of a large amount of weight can outpace the skin's ability to retract, leading to loose skin especially on the abdomen, arms, thighs, and face (see "Ozempic face" in our Muscle Loss Prevention Guide). The severity depends on the amount of weight lost, the speed of loss, age, genetics, skin quality, and sun exposure history.

Dry skin. Dehydration and reduced intake of essential fatty acids can contribute to dry, flaky skin. Ensuring adequate hydration, consuming omega-3 fatty acids (from fish, walnuts, or supplements), and using moisturizers can help.

Stretch marks. Existing stretch marks may become more visible as surrounding skin changes during weight loss. New stretch marks are unlikely during weight loss (they typically form during rapid weight gain or growth), but the appearance of existing ones may change.

Improved skin conditions. Many patients notice improvements in skin conditions associated with obesity, including acanthosis nigricans (dark, velvety skin patches in body folds), skin tags, hidradenitis suppurativa, and acne. These improvements are attributed to weight loss, improved insulin sensitivity, and reduced inflammation rather than direct medication effects.

Fatigue and Energy

Fatigue is one of the most commonly reported subjective complaints during GLP-1 therapy, affecting approximately 5-8% of patients in clinical trials and a seemingly higher proportion of patients in real-world settings. Understanding the causes of GLP-1-related fatigue helps in developing effective management strategies.

Causes of Fatigue on GLP-1 Medications

Calorie restriction. The most common cause of fatigue during GLP-1 therapy is simply eating fewer calories than your body needs. Calories are energy, and when you provide your body with significantly less energy than it requires, fatigue is a natural consequence. This is particularly pronounced during the early weeks of treatment when appetite suppression is most dramatic and patients may be eating very little.

Reduced carbohydrate intake. Carbohydrates are the body's preferred fuel source for brain function and high-intensity activity. Many GLP-1 patients dramatically reduce carbohydrate intake along with total calories. This can cause fatigue, brain fog, and reduced exercise performance, especially during the transition period before the body becomes more efficient at using fat for fuel.

Dehydration. Even mild dehydration (1-2% of body weight) can cause fatigue, reduced cognitive function, and decreased physical performance. GLP-1 patients who eat less also drink less, and those experiencing GI side effects may lose additional fluid through vomiting or diarrhea.

Nutritional deficiencies. Iron deficiency is a leading cause of fatigue, particularly in women. B12 deficiency can cause fatigue and neurological symptoms. Vitamin D deficiency causes fatigue and muscle weakness. All of these can develop or worsen when food intake is significantly reduced. A comprehensive blood panel at baseline and every 3-6 months during treatment can identify and correct these deficiencies.

Sleep disruption. Some patients report changes in sleep quality or duration while on GLP-1 medications. Nausea can disrupt sleep, especially when lying down. GERD symptoms may worsen at night. And the general stress of significant life changes (weight loss, changing body, new medication) can affect sleep. Poor sleep quality is a major contributor to daytime fatigue.

The medication itself. GLP-1 receptors in the brain are involved in energy regulation, and their activation by the medication may contribute to feelings of reduced energy in some patients. This direct effect is difficult to separate from the indirect effects of calorie restriction, but some patients report fatigue even when maintaining adequate calorie and nutrient intake.

Managing Fatigue

The following strategies can help manage fatigue during GLP-1 therapy:

• Ensure adequate calorie intake. Most adults should not drop below 1,200 calories per day for women or 1,500 calories per day for men without medical supervision. If your intake has dropped below these levels, work with your provider to adjust.
• Prioritize protein and complex carbohydrates. Include a moderate amount of complex carbohydrates (whole grains, fruits, starchy vegetables) at each meal for sustained energy. Pair them with protein for stable blood sugar.
• Stay hydrated. Aim for 64-80 ounces of water daily. Keep a water bottle accessible and set reminders to drink throughout the day.
• Check for nutritional deficiencies. Have your provider test iron (ferritin), B12, vitamin D, and thyroid function if fatigue is persistent.
• Maintain physical activity. This may seem counterintuitive, but regular moderate exercise actually increases energy levels over time. A daily walk and your resistance training sessions can help combat fatigue.
• Optimize sleep. Practice good sleep hygiene: consistent schedule, cool dark room, limited screens before bed, no caffeine after early afternoon.
• Time your injection strategically. Some patients find that fatigue peaks 1-2 days after their weekly injection. If this is your pattern, schedule your injection on a day when you can rest more easily.
• Moderate caffeine use. Moderate caffeine (200-300mg, roughly 2-3 cups of coffee) can help with energy but should be consumed before early afternoon to protect sleep.

When Fatigue Warrants Medical Evaluation

Seek medical evaluation if your fatigue is severe and debilitating (unable to complete normal daily activities), persists for more than 4-6 weeks despite adequate nutrition and rest, is accompanied by other symptoms like pale skin, shortness of breath, or chest pain (which could indicate anemia or heart issues), worsens suddenly rather than gradually, or is accompanied by significant weight loss beyond what is expected from the medication.

Side Effects by Medication: Semaglutide vs Tirzepatide vs Liraglutide

While all GLP-1 receptor agonists share a similar core side effect profile, there are meaningful differences between specific medications that can influence treatment selection and management approaches.

Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is the most widely prescribed GLP-1 medication for weight loss. It is available as a weekly subcutaneous injection (Ozempic for diabetes, Wegovy for weight management) and as a daily oral tablet (Rybelsus for diabetes).

Key side effect characteristics:

• Highest nausea rates among injectable GLP-1s (44% in STEP 1)
• Higher vomiting rates compared to tirzepatide (24% vs 13%)
• Constipation more common than with tirzepatide (24% vs 12%)
• Oral form (Rybelsus) has somewhat different GI profile with more nausea but less injection site concern
• Cardiovascular benefit demonstrated in SELECT trial

Semaglutide's higher rate of nausea and vomiting may be partly due to its slightly different receptor binding profile and pharmacokinetics. However, individual variation is large, and many patients tolerate semaglutide well while experiencing problems with other GLP-1 medications, and vice versa.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is unique in that it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action produces greater weight loss than semaglutide alone but may also produce a somewhat different side effect profile.

Key side effect characteristics:

• Somewhat lower nausea and vomiting rates than semaglutide at equivalent weight loss levels
• Higher diarrhea rates at higher doses (23% at 15mg)
• Higher injection site reaction rates (7% vs 4% for semaglutide)
• Slightly higher hair loss rates (5.2% at 15mg in SURMOUNT-1)
• Greater weight loss per level of GI side effects (better "efficacy-tolerability ratio")

The dual GIP/GLP-1 mechanism of tirzepatide may explain some of these differences. GIP receptor activation has different effects on gut motility than GLP-1 receptor activation alone, potentially producing a somewhat different GI side effect pattern. Some providers consider tirzepatide as a first-line option for patients who are particularly concerned about nausea.

Liraglutide (Saxenda, Victoza)

Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management (as Saxenda). It is a daily injection, which means more frequent dosing but also more flexibility in dose timing.

Key side effect characteristics:

• Lower peak side effect severity because daily dosing produces more stable drug levels
• Higher overall discontinuation rate (10% vs 7% for semaglutide) despite lower per-episode severity
• More injection site reactions due to daily injections (more total injections means more opportunities for reactions)
• Longest safety track record (over 15 years of data)
• Less weight loss efficacy, which may mean less aggressive side effects for some patients

Liraglutide is sometimes preferred for patients who want a more gradual approach, those who want the longest safety track record, or those who experience severe side effects with weekly injectables and prefer the smaller, more frequent doses of a daily medication.

For a detailed comparison of semaglutide and tirzepatide including efficacy, cost, and availability, see our Semaglutide vs Tirzepatide Comparison Guide. For guidance on switching between medications, see our Switching GLP-1 Medications Guide.

Side Effects by Dose Level

GLP-1 side effects are dose-dependent, meaning they generally become more frequent and sometimes more severe at higher doses. This is why all GLP-1 medications for weight loss use a gradual dose-escalation approach, starting at the lowest dose and increasing every 4 weeks. Understanding how side effects change with dose helps you anticipate what to expect during escalation.

Semaglutide Dose Escalation Schedule and Side Effects

The standard semaglutide dose escalation for weight management (Wegovy) is:

• Weeks 1-4: 0.25 mg weekly. This is a sub-therapeutic "introductory" dose. Most patients experience minimal to mild side effects. Nausea occurs in approximately 15-20% of patients at this dose and is usually mild.
• Weeks 5-8: 0.5 mg weekly. Side effects increase modestly. Nausea affects approximately 25-30% of patients. This is where most patients first notice significant appetite suppression.
• Weeks 9-12: 1.0 mg weekly. This is the first dose where meaningful weight loss typically begins. GI side effects peak again briefly with the dose increase. Nausea affects approximately 35% of patients.
• Weeks 13-16: 1.7 mg weekly. Another step up with potential for increased GI symptoms. Some patients find this is their optimal dose and do not need to escalate further.
• Week 17+: 2.4 mg weekly (target dose). This is the full dose used in the STEP trials. GI side effects are most frequent at this dose (44% nausea, 24% vomiting in STEP 1). However, by this point, the body has had 16+ weeks to adapt, and many patients tolerate this dose well.

Not all patients need to reach the maximum dose. If you are achieving satisfactory weight loss at a lower dose with manageable side effects, your provider may recommend staying at that dose. The goal is to find the lowest effective dose that balances weight loss efficacy with tolerability.

Tirzepatide Dose Escalation Schedule and Side Effects

The standard tirzepatide dose escalation for weight management (Zepbound) is:

• Weeks 1-4: 2.5 mg weekly. Introductory dose with mild side effects. Nausea in approximately 12-18% of patients.
• Weeks 5-8: 5 mg weekly. First clinically effective dose. GI side effects increase. Nausea in approximately 20-24%.
• Weeks 9-12: 7.5 mg weekly (optional). Intermediate dose for patients who need more than 5 mg but have difficulty tolerating 10 mg.
• Weeks 13-16: 10 mg weekly. GI side effects at moderate levels. Nausea in approximately 25-28%. Significant weight loss typically occurring.
• Weeks 17-20: 12.5 mg weekly (optional). Intermediate step before the maximum dose.
• Week 21+: 15 mg weekly (maximum dose). Highest efficacy and highest side effect rates. Nausea in approximately 31% in SURMOUNT-1.

Slower Dose Escalation: An Option for Sensitive Patients

For patients who experience significant side effects during the standard escalation schedule, a slower approach can be beneficial. Instead of increasing the dose every 4 weeks, extending each dose level to 6-8 weeks gives the body more time to adapt. Some providers use "micro-titration" approaches, using compounded doses that allow even smaller incremental increases. For example, instead of jumping from 0.5 mg to 1.0 mg of semaglutide, a patient might step through 0.6, 0.7, 0.8, and 0.9 mg over several weeks.

A slower escalation means reaching the target dose takes longer, but it often results in better tolerability, fewer missed doses, and better long-term adherence. The total weight loss outcome is generally similar regardless of whether you reach the target dose in 16 weeks or 24 weeks.

For more information about compounded GLP-1 medications and their dosing flexibility, see our GLP-1 Compounding Pharmacy Guide.

Management Strategies for Every Side Effect

Effective side effect management is key to completing a successful course of GLP-1 therapy. Most side effects can be significantly reduced or eliminated with the right strategies. This section provides a comprehensive management protocol organized by symptom.

Nausea Management Protocol

Dietary modifications:

• Eat 4-6 small meals instead of 2-3 large ones.
• Avoid fatty, greasy, fried, or very spicy foods during nausea episodes.
• Eat slowly and stop at the first sign of fullness. Overeating is the most common trigger for severe nausea.
• Try bland foods: crackers, toast, rice, bananas, applesauce.
• Cold foods are often better tolerated than hot foods when nauseous.
• Separate liquids from solids: drink water between meals rather than during meals.

Natural remedies:

• Ginger: Fresh ginger tea, ginger chews, ginger capsules (250mg, 4 times daily), or ginger ale (real ginger, not flavoring).
• Peppermint: Peppermint tea or peppermint oil capsules can soothe the stomach.
• Acupressure: Pressing the P6 (Nei Guan) point on the inner wrist has evidence for reducing nausea. Sea-Band wristbands apply continuous pressure to this point.
• Fresh air and gentle movement: A short walk in fresh air can reduce nausea episodes.
• Deep breathing: Slow, deep breaths activate the parasympathetic nervous system and can reduce nausea.

Medical treatments (discuss with your provider):

• Ondansetron (Zofran): The most commonly prescribed anti-nausea medication for GLP-1 patients. Dissolving tablets provide rapid relief.
• Promethazine (Phenergan): An alternative anti-emetic that also has sedating properties.
• Metoclopramide (Reglan): Helps speed gastric emptying, counteracting one of the mechanisms causing nausea. Use should be limited due to side effects with long-term use.
• Dose adjustment: Slower escalation or a lower maintenance dose can significantly reduce nausea.

Constipation Management Protocol

• First line: Increase water intake to 80+ ounces daily, add fiber through fruits, vegetables, and whole grains, maintain daily physical activity.
• Second line: Add a fiber supplement (psyllium husk, 1-2 tablespoons daily with water), try a stool softener (docusate sodium, 100mg 1-2 times daily).
• Third line: Osmotic laxative (polyethylene glycol/Miralax, 17g daily dissolved in water). This is safe for regular use.
• As needed: Magnesium citrate or milk of magnesia for acute episodes. Glycerin suppositories for immediate relief.
• Avoid: Regular use of stimulant laxatives (senna, bisacodyl) without medical supervision.

Diarrhea Management Protocol

• Stay well hydrated with water and electrolyte solutions.
• Follow the BRAT diet during acute episodes (bananas, rice, applesauce, toast).
• Avoid dairy, fatty foods, high-fiber foods, caffeine, and artificial sweeteners temporarily.
• Loperamide (Imodium) can be used for acute episodes but should not be used regularly without medical advice.
• Probiotics may help restore normal gut flora.
• If diarrhea is severe or contains blood, contact your provider.

GERD Management Protocol

• Eat smaller meals, especially in the evening.
• Avoid eating 3+ hours before bedtime.
• Elevate the head of your bed 6-8 inches (use blocks or a wedge pillow).
• Avoid trigger foods: citrus, tomatoes, chocolate, coffee, alcohol, spicy foods, mint.
• Over-the-counter antacids (Tums, Rolaids) for occasional episodes.
• H2 blockers (famotidine/Pepcid) for more frequent episodes.
• Proton pump inhibitors (omeprazole/Prilosec) for persistent GERD, ideally limited to 2-4 week courses.

Headache Management Protocol

• Ensure adequate hydration (headaches often result from dehydration).
• Maintain regular meals to prevent blood sugar drops.
• Acetaminophen (Tylenol) or ibuprofen (Advil) for acute headaches.
• Limit caffeine changes (suddenly stopping caffeine can cause withdrawal headaches).
• If headaches are severe or persistent, contact your provider.

Fatigue Management Protocol

• Ensure calorie intake is not dangerously low (minimum 1,200 cal for women, 1,500 for men).
• Include complex carbohydrates at each meal for sustained energy.
• Stay hydrated.
• Check for nutritional deficiencies (iron, B12, vitamin D, thyroid).
• Maintain regular physical activity and sleep schedule.
• Limit caffeine to mornings only.
• If severe, discuss dose adjustment with your provider.

Injection Site Reaction Management

• Rotate injection sites systematically (abdomen one week, thigh the next, upper arm the next).
• Allow medication to reach room temperature before injecting.
• Use proper technique with a quick, confident insertion.
• Apply ice before injection if pain is a concern.
• Do not rub the injection site after injection.
• Antihistamine cream or oral antihistamine for itching.
• Contact your provider if reactions are spreading, worsening, or show signs of infection.

When to Call Your Doctor vs Go to the ER

Knowing when a side effect requires medical attention and how urgently can be challenging. This section provides clear guidance on triaging GLP-1 side effects.

Self-Manageable at Home

The following side effects can typically be managed at home with the strategies described in this guide:

• Mild to moderate nausea that responds to dietary changes and natural remedies
• Occasional episodes of diarrhea or constipation
• Mild headache
• Mild fatigue
• Minor injection site redness or bruising
• Mild bloating or gas
• Reduced appetite (this is the intended effect)
• Minor taste changes

Call Your Doctor (Non-Urgent, Within 1-2 Days)

Contact your prescribing provider for these concerns:

• Nausea that does not improve after 2-3 weeks at the same dose
• Constipation lasting more than 5 days despite management
• Diarrhea lasting more than a week
• Persistent GERD that does not respond to over-the-counter treatments
• Hair loss that is more than minimal shedding
• New or worsening mood changes (depression, anxiety, irritability)
• Persistent fatigue despite adequate nutrition and sleep
• Injection site reactions that persist beyond 1 week
• Mild weight loss that is faster than expected (more than 3-4 lbs per week consistently)
• Concerns about medication interactions

Call Your Doctor Urgently (Same Day)

Seek same-day medical contact for:

• Vomiting that prevents keeping food or fluids down for more than 12 hours
• Significant diarrhea with signs of dehydration (dizziness, dark urine, dry mouth)
• Moderate abdominal pain that is persistent and worsening
• Pain in the right upper abdomen, especially after meals (possible gallbladder)
• New or worsening thoughts of self-harm
• Spreading injection site redness or signs of infection
• Significant hypoglycemia symptoms (shakiness, sweating, confusion) in diabetic patients

Go to the Emergency Room

Seek emergency care immediately for:

• Severe abdominal pain, especially radiating to the back (possible pancreatitis)
• Inability to keep any fluids down for 24+ hours
• Signs of severe allergic reaction: facial/throat swelling, difficulty breathing, widespread hives
• Very dark or bloody urine, minimal urine output (possible kidney injury)
• Bloody stool or vomiting blood
• Severe right upper abdominal pain with fever (possible acute cholecystitis)
• Confusion, loss of consciousness, or seizure
• Chest pain or severe shortness of breath
• Complete inability to pass gas or stool with severe abdominal distension (possible obstruction)
• Active suicidal thoughts or plans

Long-Term Safety Data

One of the most important questions patients ask is whether GLP-1 medications are safe for long-term use. As many patients take these medications for years or even indefinitely, the long-term safety profile is critical. Fortunately, the available data, spanning up to 15 years for the GLP-1 class, is generally reassuring.

Cardiovascular Safety and Benefits

The most strong long-term safety data comes from cardiovascular outcome trials (CVOTs), which were originally designed to ensure GLP-1 medications did not increase heart risk. These trials not only demonstrated safety but revealed significant cardiovascular benefits.

The SELECT trial, which followed patients on semaglutide 2.4 mg for a median of 39.8 months (over 3 years), demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death). This was the first cardiovascular benefit demonstrated by a weight loss medication in people without diabetes. The safety profile during this extended follow-up was consistent with shorter trials, with no new safety signals emerging.

Earlier CVOTs for diabetes-dose GLP-1 medications, including LEADER (liraglutide, 3.8 years), SUSTAIN-6 (semaglutide, 2.1 years), and REWIND (dulaglutide, 5.4 years), similarly demonstrated cardiovascular safety or benefit without new long-term concerns. For a detailed analysis of GLP-1 cardiovascular benefits, see our GLP-1 Heart Health Guide.

Thyroid Safety in Long-Term Follow-Up

Despite the boxed warning about medullary thyroid carcinoma based on rodent studies, over 15 years of human data from the GLP-1 class has not demonstrated an increased risk of thyroid cancer. A large 2024 cohort study analyzing health records of over 2 million GLP-1 users found no statistically significant increase in thyroid cancer incidence compared to non-users. Ongoing pharmacovigilance continues to monitor this potential risk.

Pancreatic Safety

Early concerns about GLP-1 medications potentially causing pancreatic cancer or chronic pancreatic damage have not been confirmed in long-term data. The CVOTs, which followed patients for 2-5 years, did not show increased rates of pancreatic cancer. The acute pancreatitis risk remains at approximately 0.2-0.4%, consistent with shorter studies. Monitoring for pancreatitis symptoms remains important, but the overall pancreatic safety profile appears favorable.

Kidney and Liver Effects

Long-term data suggests that GLP-1 medications may actually provide kidney protection in patients with diabetes. The FLOW trial, completed in 2024, demonstrated that semaglutide reduced the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease. For weight loss patients without diabetes or pre-existing kidney disease, long-term kidney safety data is reassuring, with no signal for kidney toxicity beyond the dehydration-related AKI risk discussed earlier.

Liver effects appear neutral to beneficial. Some studies have shown improvements in non-alcoholic fatty liver disease (NAFLD) markers in patients taking GLP-1 medications, likely related to weight loss and improved metabolic parameters.

Bone Health

An emerging area of monitoring is the effect of GLP-1-mediated weight loss on bone density. Any significant weight loss reduces the mechanical loading on bones, which can decrease bone density over time. Some studies have shown modest decreases in bone mineral density during GLP-1 therapy, particularly in patients with the most rapid weight loss. However, the clinical significance (whether this translates to increased fracture risk) is not yet clear. Patients at high risk for osteoporosis should have bone density monitored during treatment.

Drug Interactions: Long-Term Considerations

For patients taking GLP-1 medications alongside other long-term medications, ongoing attention to drug interactions is important. The delayed gastric emptying effect of GLP-1 medications can alter the absorption of oral medications. Key interactions to monitor include:

• Oral contraceptives: Delayed absorption may reduce effectiveness. Backup contraception should be used during the first month of GLP-1 therapy and after dose increases.
• Levothyroxine (thyroid medication): Absorption may be altered. Monitor thyroid levels and adjust dose as needed.
• Warfarin (blood thinner): Monitor INR more frequently, especially during dose changes.
• Diabetes medications (insulin, sulfonylureas): Dose reductions are often needed to prevent hypoglycemia as weight loss improves insulin sensitivity.
• Blood pressure medications: Dose reductions may be needed as weight loss lowers blood pressure.

What We Still Do Not Know

Despite the encouraging safety data, there are areas where long-term data is still accumulating:

• Safety beyond 5 years for weight-loss doses (2.4 mg semaglutide and high-dose tirzepatide)
• Effects on fertility and pregnancy when medication is used long-term before conception
• Long-term effects on muscle mass, bone density, and metabolic rate
• Whether benefits are maintained after many years of continuous use
• Long-term mental health effects in large populations
• Generational effects (effects on children of long-term users)

These unknowns are typical for any medication class and are being addressed through ongoing studies and post-marketing surveillance. The current benefit-risk profile is considered favorable by major medical organizations for appropriate patients.

Frequently Asked Questions About GLP-1 Side Effects

References

Clinical Trials and Prescribing Information

• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373(1):11-22.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
• Novo Nordisk. Wegovy (semaglutide) prescribing information. 2024.
• Eli Lilly. Zepbound (tirzepatide) prescribing information. 2024.

Safety and Post-Marketing Data

• Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
• Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
• Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486.
• FDA. FDA reviewing reports of suicidal thoughts or actions in patients taking certain type of GLP-1 receptor agonist medicines. Safety Communication. 2023.

Side Effect Management and Clinical Practice

• Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563.
• Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021;46:101102.
• Drucker DJ. The GLP-1 process: from discovery science to therapeutic impact. J Clin Invest. 2024;134(2):e175634.
• Stokes CS, Gluud LL, Castera L, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014;12(7):1090-1100.